Clinical trials: Locally Advanced Resectable Esophageal Squamous Cell Carcinoma, open to volunteers
Esophageal Squamour Cell Cancer
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Neoadjuvant ChemoRadioTherapy (NCRT) combined with surgical resection is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) based on CROSS and 5010 study.
- Trial name
- NCT06814158
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This single center, prospective, single arm clinical study aims to evaluate the clinical efficacy and safety of Envafolimab combined with albumin bound paclitaxel and carboplatin as neoadjuvant therapy for locally advanced…
- Trial name
- NCT07266493
- Testing
- Chemotherapy （Albumin bound paclitaxel and Carboplatin）
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Zhongshan Hospital
Late-stage Resectable Esophageal Squamous Carcinoma
Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
This study is a prospective, exploratory clinical study aimed at evaluating the feasibility and safety of camrelizumab combined with synchronous chemoradiotherapy as an organ-preserving strategy for locally advanced resectable…
- Trial name
- NCT07622797
- Testing
- Camrelizumab (anti-PD-1 inhibitor), Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 164 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Esophageal Squamous Cell Carcinoma (ESCC)
Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This clinical trial aims to preliminarily evaluate the efficacy and safety of adebrelimab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for borderline resectable locally advanced esophageal…
- Trial name
- NEOCRTEC2501 (NCT07638436)
- Testing
- Adebrelimab Injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma, Ivonescimab
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined with Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for Resectable, Locally Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Ivonescimab, Neoadjuvant
- Trial name
- NCT07385001
- Testing
- AK112, AK112 + Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Tang-Du Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
This study is a randomized, controlled, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of neoadjuvant toripalimab in combination with nab-paclitaxel and platinum versus neoadjuvant…
- Trial name
- TD-NEOE3V3 (NCT06952621)
- Testing
- 3 cycles (Toripalimab + chemotherapy), 3 cycles（DCF）
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Tang-Du Hospital
Resectable Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
This trial is conducted in patients with resectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 46 patients with resectable locally advanced esophageal cancer in Tianjin cancer hospital.
- Trial name
- NCT07457528
- Testing
- HLX10, Chemotherapy, Nimotuzumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer (EsC)
A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
This study is a prospective, observational clinical study. In this study, 30 patients with resectable locally advanced esophageal squamous carcinoma will be prospectively enrolled and treated with adebrelimab (SHR-1316) combined…
- Trial name
- NCT06869213
- Testing
- Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
This is a randomized, controlled, multi-center phase II/III study. All patients are resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT07263919
- Testing
- Cadonilimab (AK104), Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Akeso
Esophageal Squamous Cell Carcinoma
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
This study aims to evaluate the impact of the neoadjuvant treatment strategy based on CPS score on the pathological complete response (pCR) rate in patients with resectable locally advanced esophageal cancer.
- Trial name
- ESCC (NCT06601309)
- Testing
- Serplulimab, Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy), Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fujian Medical University Union Hospital
Esophageal Squamous Cell Carcinoma
Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）
Based on our previous single-arm Phase Ib study (CRIS trial, NCT06303583), we observed that neoadjuvant chemoradiotherapy followed by immunotherapy (nCRIT) significantly increased the pathological complete response (pCR) rate…
- Trial name
- NCT06509568
- Testing
- Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zhejiang Cancer Hospital
ESCC
Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2)
This is a prospective, single-center, randomized phase 2 study of adebrelimab plus full-course neoadjuvant therapy in resectable locally advanced esophageal squamous cell carcinoma.
- Trial name
- NAT-ESCC-01 (NCT07584031)
- Testing
- Combination therapy with chemotherapy and immunotherapy, Surgery
- Volunteers
- 200 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma
Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
This is a multicenter, open-label, randomized, controlled clinical study to compare the efficacy and safety of cardonilizumab combined with neoadjuvant chemotherapy and surgery versus neoadjuvant chemoradiotherapy and surgery in…
- Trial name
- NCT07699185
- Testing
- Cardonilizumab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Tongji Hospital
Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
The purpose of this study was to evaluate the safety, feasibility and outcome of anti-PD-1 antibody (Tislelizumab, BeiGene) combined with neoadjuvant chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by minimally…
- Trial name
- iCROSS (NCT04973306)
- Testing
- Neoadjuvant Chemoradiotherapy, Tislelizumab, Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
Esophageal cancer is a malignant tumor with high incidence rate and mortality in China. According to the data of the World Health Organization, 324000 new cases and 301000 deaths of esophageal cancer will occur in China in 2020…
- Trial name
- NCT06861777
- Testing
- Adebrelimab + paclitaxel/nab-paclitaxel + cisplatin followed by chemoradiotherapy, chemoradiotherapy followed by adebrelimab + paclitaxel/nab-paclitaxel + cisplatin, TNT treatment [TNT group one (phase 2) or TNT group two (phase 2)]
- Where
- China
- Volunteers
- 474 people
- Sponsor
- YIN LI
ESCC
Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Major objectives to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706,an Anti-PD-1/CTLA-4 Combined Antibody) combined with Nab-Paclitaxel in neoadjuvant therapy for patients with locally advanced…
- Trial name
- NCT07493993
- Testing
- lparomlimab and Tuvonralimab Injection in Combination with Nab-Paclitaxel
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Neoadjuvant QL1706 Therapy for ESCC
This study plans to enroll 32 patients with resectable esophageal squamous cell carcinoma. The treatment regimen consists of Iparomlimab and Tuvonralimab(QL1706) combined with chemotherapy: intravenous infusion of QL1706 (5…
- Trial name
- NCT06908382
- Testing
- Iparomlimab and Tuvonralimab Injection
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Shandong Provincial Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Neoadjuvant Short-Course Radiotherapy Followed by Tislelizumab Plus Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma This is a prospective, randomized, two-arm, parallel-group, multicenter…
- Trial name
- NCT07678580
- Testing
- Albumin-bound paclitaxel, Low-dose Short-course Radiotherapy, High-dose Short-course Radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tang-Du Hospital
Esophageal Squamous Cell Carcinoma
Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Locally advanced Esophageal Squamous Cell Carcinoma (ESCC) has poor prognosis with standard therapies. Neoadjuvant immunochemotherapy improves pathological response rates, but optimal regimens remain undefined.
- Trial name
- NCT07799077
- Testing
- Paclitaxel polymer micelles for injection and cisplatin combined with sintilimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Hebei Medical University Fourth Hospital
Locally Advanced Esophageal Squamous Cell Carcinoma
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if cadonilimab combined with anlotinib can be a safe and effective neoadjuvant therapy in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06426797
- Testing
- Cadonilimab plus anlotinib
- Volunteers
- 25 people
- Sponsor
- Peking University People's Hospital